J Cell Sci Ther 2015 – β-Glucan – from Food Supplement to a Licensed Drug.  CONCLUSION:  All these new findings mentioned above open the window for β-glucan to become a licensed drug. In addition to effects in anti-infectious and anti-cancer immunity, novel studies clearly demonstrated significant palliative effects of β-glucan in allergy, arthritis, gastrointestinal tract diseases, stress reduction and reduction of cholesterol levels (for review see [5]). With over 60 clinical trials currently running, the question of whether other countries will follow Japan, where β-glucan is officially used since 1983, is not if, but when.  Read more…